ClinicalTrials.gg
CompletedNCT06907329Updated Nov 3, 2026

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metabolism in Middle-aged and Elderly Individuals With Metabolic Disorders.

An interventional study of NMN and Placebo in Immunosenescence, Overweight and Obesity, sponsored by Qing Su. Completed at 1 site in China. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Qing Su · Not applicable, Interventional, and Other

How we know

Updated Nov 3, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Enrollment
235th of 504
124 · median 120
Started
2025
with 114 others
No phase
213 of 603
73 open now
Registered
334th of 603
by date

Among the 603 studies in Obesity with a site in China, this one is the 235th largest by enrollment of the 504 interventional ones that give a count, is one of 115 that started in 2025, is one of 213 with no phase, and was the 334th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. The main assessment is the change from baseline in the proportion of a blood T-cell population associated with immune system aging. The study also evaluates liver fat, blood sugar regulation, body composition, other immune and metabolic markers, and cardiorespiratory fitness, together with laboratory measures of safety.

Read the detailed description

This single-center, randomized, placebo-controlled, parallel-group study evaluates the effects of nicotinamide mononucleotide (NMN) sustained-release tablets on immunosenescence and metabolism in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. A total of 124 participants were enrolled. Participants were randomly assigned to receive NMN sustained-release tablets (1,000 mg per tablet) or matching placebo, one tablet daily before breakfast for 26 weeks. Study visits were scheduled at months 1, 3, and 6.

The primary outcome is the change from baseline to Week 26 in the percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood, measured by flow cytometry. The change is calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

Secondary assessments include other T-cell phenotypes, the CD8/CD4 ratio expressed as a percentage, hepatic steatosis, glucose metabolism, pancreatic beta-cell function, insulin resistance, body composition, anthropometric measures, whole-blood NMN and NAD+ concentrations, relative telomere length, and cardiorespiratory fitness. Hepatic steatosis is assessed using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and the controlled attenuation parameter (CAP) measured by FibroScan. Body composition outcomes, assessed by dual-energy X-ray absorptiometry (DXA), are total body fat mass, total body tissue fat percentage, total body lean mass, estimated visceral adipose tissue mass, and relative skeletal muscle index. Cardiorespiratory fitness outcomes, assessed by cardiopulmonary exercise testing, are peak oxygen uptake and oxygen uptake at the anaerobic threshold. Each secondary outcome is assessed as the change from baseline to Week 26 and analyzed separately.

Safety assessments include routine blood and urine tests and liver and kidney function tests.

03

Conditions studied

  • Immunosenescence
  • Overweight
  • Obesity
  • Metabolic Dysfunction-Associated Fatty Liver Disease
  • Prediabetic State
  • Diabetes Mellitus, Type 2

Browse trials for

Keywords

  • Nicotinamide mononucleotide
  • NMN
  • NAD+
  • T-cell senescence
  • CD28
  • Aging
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 124 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

This is the only study on the registry with Qing Su as lead sponsor.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Age 50-70 years with overweight or obesity ( ≥ 24 kg/m²);
  • (2) At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with \<7% without glucose-lowering drug therapy;
  • (3) Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the form.

Exclusion criteria

Exclusion Criteria:

  • (1) Patients with tumours;
  • (2) Patients with diseases (excluding Hashimoto's thyroiditis);
  • (3) Severe cardiovascular disease or cardiac insufficiency;
  • (4) Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg;
  • (5) ;
  • (6) Chronic active hepatitis or cirrhosis;
  • (7) Chronic renal insufficiency;
  • (8) Stroke patients;
  • (9) Severe haematological diseases;
  • (10) Infectious diseases;
  • (11) Mental illness;
  • (12) Other conditions that, in the opinion of the investigator, may affect the results of the study;
  • (13) Those who have used NMN or other anti-aging agents within six months;
  • (14) Premenopausal women;
  • (15) , AST values are more than three times higher than the reference range;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    NMN Arm

    Participants assigned to the NMN arm receive one sustained-release tablet containing 1,000 mg of nicotinamide mononucleotide orally once daily before breakfast for 26 weeks.

    Dietary Supplement: NMN

  • Placebo comparator
    Placebo Arm

    Participants assigned to the placebo arm receive one matching placebo tablet orally once daily before breakfast for 26 weeks.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementNicotinamide MononucleotideStudies of Nicotinamide MononucleotideNicotinamide Mononucleotide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nicotinamide mononucleotide (NMN) sustained-release tablets, 1,000 mg per tablet, administered orally as one tablet once daily before breakfast for 26 weeks.

  • Dietary supplementPlacebo

    Matching placebo tablets, administered orally as one tablet once daily before breakfast for 26 weeks.

07

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T Cells Among Total CD3+CD8+ T Cells

    The percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27- T Cells Among Total CD3+CD8+ T Cells

    The percentage of CD3+CD8+CD27- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  2. Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD28- T Cells Among Total CD3+CD8+ T Cells

    The percentage of CD3+CD8+CD28- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  3. Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27- T Cells Among Total CD3+CD4+ T Cells

    The percentage of CD3+CD4+CD27- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  4. Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD28- T Cells Among Total CD3+CD4+ T Cells

    The percentage of CD3+CD4+CD28- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  5. Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27-CD28- T Cells Among Total CD3+CD4+ T Cells

    The percentage of CD3+CD4+CD27-CD28- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  6. Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD45RA+CCR7- T Cells Among Total CD3+CD8+ T Cells

    The percentage of CD3+CD8+CD45RA+CCR7- T cells (TEMRA cells) among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  7. Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD57+KLRG1+ T Cells Among Total CD3+CD8+ T Cells

    The percentage of CD3+CD8+CD57+KLRG1+ T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  8. Change From Baseline to Week 26 in the CD3+CD8+ to CD3+CD4+ T-Cell Ratio Expressed as a Percentage

    CD3+CD8+ and CD3+CD4+ T cells in peripheral blood will be quantified by flow cytometry. The CD8/CD4 ratio will be expressed as a percentage by dividing the number of CD3+CD8+ T cells by the number of CD3+CD4+ T cells and multiplying by 100. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  9. Change From Baseline to Week 26 in Liver Fat Content Assessed by MRI-PDFF

    Liver fat content will be assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and expressed as a percentage. Change from baseline will be calculated as the Week 26 MRI-PDFF percentage minus the baseline MRI-PDFF percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  10. Change From Baseline to Week 26 in Controlled Attenuation Parameter (CAP)

    Hepatic steatosis will be assessed using the controlled attenuation parameter (CAP) measured by FibroScan and expressed in dB/m. Change from baseline will be calculated as the Week 26 CAP value minus the baseline CAP value.

    Time frame: Baseline and Week 26

  11. Change From Baseline to Week 26 in Fasting Blood Glucose

    Fasting blood glucose will be measured in venous blood and expressed in mmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  12. Change From Baseline to Week 26 in 2-Hour Blood Glucose During an Oral Glucose Tolerance Test

    Blood glucose at 2 hours during an oral glucose tolerance test (OGTT) will be measured in venous blood and expressed in mmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  13. Change From Baseline to Week 26 in Glycated Hemoglobin (HbA1c)

    Glycated hemoglobin (HbA1c) will be measured in whole blood and expressed as a percentage (%) of total hemoglobin. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  14. Change From Baseline to Week 26 in HOMA-beta

    Pancreatic beta-cell function will be assessed using the homeostasis model assessment of beta-cell function (HOMA-beta), calculated from fasting glucose and fasting insulin and reported as an index. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  15. Change From Baseline to Week 26 in HOMA-IR

    Insulin resistance will be assessed using the homeostasis model assessment of insulin resistance (HOMA-IR), calculated from fasting glucose and fasting insulin and reported as a unitless index. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  16. Change From Baseline to Week 26 in Total Body Fat Mass Assessed by DXA

    Total body fat mass will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  17. Change From Baseline to Week 26 in Total Body Tissue Fat Percentage Assessed by DXA

    Total body tissue fat percentage (fat mass as a percentage of total tissue mass) will be measured by whole-body dual-energy X-ray absorptiometry (DXA). Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.

    Time frame: Baseline and Week 26

  18. Change From Baseline to Week 26 in Total Body Lean Mass Assessed by DXA

    Total body lean mass will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  19. Change From Baseline to Week 26 in Estimated Visceral Adipose Tissue Mass Assessed by DXA

    Visceral adipose tissue mass will be estimated by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  20. Change From Baseline to Week 26 in Relative Skeletal Muscle Index (RSMI) Assessed by DXA

    Relative skeletal muscle index (RSMI), calculated as appendicular lean mass divided by height squared, will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in kg/m\^2. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  21. Change From Baseline to Week 26 in Body Weight

    Body weight will be measured using a weighing scale and expressed in kilograms. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  22. Change From Baseline to Week 26 in Waist Circumference

    Waist circumference will be measured using a tape measure and expressed in centimeters. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  23. Change From Baseline to Week 26 in Waist-to-Hip Ratio

    Waist and hip circumferences will be measured using a standardized tape measure following WHO measurement protocols. The waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference, using the same units for both measurements. The ratio is unitless. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  24. Change From Baseline to Week 26 in Waist-to-Height Ratio

    Waist circumference and height will be measured following WHO measurement protocols. The waist-to-height ratio will be calculated by dividing waist circumference by height, using the same units for both measurements. The ratio is unitless. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  25. Change From Baseline to Week 26 in Whole-Blood Nicotinamide Mononucleotide (NMN) Concentration

    Nicotinamide mononucleotide (NMN) concentration will be measured in whole blood and expressed in nmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  26. Change From Baseline to Week 26 in Whole-Blood Nicotinamide Adenine Dinucleotide (NAD+) Concentration

    The concentration of oxidized nicotinamide adenine dinucleotide (NAD+) will be measured in whole blood and expressed in micromol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  27. Change From Baseline to Week 26 in Relative Telomere Length in Peripheral Blood Cells

    Relative telomere length in peripheral blood cells will be measured by quantitative real-time polymerase chain reaction (qPCR) and reported as a unitless value. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  28. Change From Baseline to Week 26 in Peak Oxygen Uptake (Peak VO2)

    Peak oxygen uptake will be measured during cardiopulmonary exercise testing and expressed in mL/min. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

  29. Change From Baseline to Week 26 in Oxygen Uptake at the Anaerobic Threshold (VO2-AT)

    Oxygen uptake at the anaerobic threshold will be measured during cardiopulmonary exercise testing and expressed in mL/min. Change from baseline will be calculated as the Week 26 value minus the baseline value.

    Time frame: Baseline and Week 26

08

Study locations

1 site
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Oct 2026, 16 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 16 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Mar 2027 → Oct 2026 and completion Mar 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Apr 2, 2025
StartActual
Jun 5, 2025
Primary completionActual
Oct 18, 2026was Mar 2027
CompletionActual
Oct 18, 2026was Mar 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Primary completion
Mar 31, 2027→Oct 18, 2026 (actual)
Nov 3, 2026
Study completion
Mar 31, 2027→Oct 18, 2026 (actual)
Nov 3, 2026
Enrollment
126 (estimated)→124 (actual)
Nov 3, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited(1) Age 50-70 years with overweight or obesity (BMI 24kg≥ 24 kg/m2m²);
Exclusion criteria
  • ChangedBefore Premenopausal womanNow (14) Premenopausal women;
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T cells as a percentage ofCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
Nov 3, 2026
Secondary outcomes
7 edited, 22 added, 1 removed, 11 more
What changed in the outcomes
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD27- T cells as a percentage of totalCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD28- T cells as a percentage of totalCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD4+CD27- T cells as a percentage ofCells Among Total CD3+CD4+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD4+CD28- T cells as a percentage ofCells Among Total CD3+CD4+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD4+CD27-CD28- T cells as a percentage ofCells Among Total CD3+CD4+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD45RA+CCR7- T cells as a percentage ofCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
  • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD57+KLRG1+ T cells as a percentage ofCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
  • AddedChange From Baseline to Week 26 in the CD3+CD8+ to CD3+CD4+ T-Cell Ratio Expressed as a PercentageTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Liver Fat Content Assessed by MRI-PDFFTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Controlled Attenuation Parameter (CAP)Time frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Fasting Blood GlucoseTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in 2-Hour Blood Glucose During an Oral Glucose Tolerance TestTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Glycated Hemoglobin (HbA1c)Time frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in HOMA-betaTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in HOMA-IRTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Total Body Fat Mass Assessed by DXATime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Total Body Tissue Fat Percentage Assessed by DXATime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Total Body Lean Mass Assessed by DXATime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Estimated Visceral Adipose Tissue Mass Assessed by DXATime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Relative Skeletal Muscle Index (RSMI) Assessed by DXATime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Body WeightTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Waist CircumferenceTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Waist-to-Hip RatioTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Waist-to-Height RatioTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Whole-Blood Nicotinamide Mononucleotide (NMN) ConcentrationTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Whole-Blood Nicotinamide Adenine Dinucleotide (NAD+) ConcentrationTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Relative Telomere Length in Peripheral Blood CellsTime frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Peak Oxygen Uptake (Peak VO2)Time frame: Baseline and Week 26
  • AddedChange From Baseline to Week 26 in Oxygen Uptake at the Anaerobic Threshold (VO2-AT)Time frame: Baseline and Week 26
  • RemovedBody composition analysis, expressed in kg, %, and g/cm², evaluated by dual-energy X-ray absorptiometryTime frame: 26 weeks
  • …and 11 more, on the record history on ClinicalTrials.gov ↗
Nov 3, 2026
Title
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and MetablismMetabolism in Middle-aged and Elderly Individuals With Metabolic Disorders.
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Recruiting→Completed
    Primary completion Mar 31, 2027→Oct 18, 2026 (now actual)
    Study completion Mar 31, 2027→Oct 18, 2026 (now actual)
    Enrollment 126 (estimated)→124 (actual)
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited(1) Age 50-70 years with overweight or obesity (BMI 24kg≥ 24 kg/m2m²);
    Exclusion criteria
    • ChangedBefore Premenopausal womanNow (14) Premenopausal women;
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T cells as a percentage ofCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    Secondary outcomes 7 edited, 22 added, 1 removed, 11 more
    What changed in the outcomes
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD27- T cells as a percentage of totalCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD28- T cells as a percentage of totalCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD4+CD27- T cells as a percentage ofCells Among Total CD3+CD4+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD4+CD28- T cells as a percentage ofCells Among Total CD3+CD4+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD4+CD27-CD28- T cells as a percentage ofCells Among Total CD3+CD4+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD45RA+CCR7- T cells as a percentage ofCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    • EditedChange From Baseline to Week 26 in the Percentage of CD3+CD8+CD57+KLRG1+ T cells as a percentage ofCells Among Total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometryCellsTime frame: 26 weeks → Baseline and Week 26
    • AddedChange From Baseline to Week 26 in the CD3+CD8+ to CD3+CD4+ T-Cell Ratio Expressed as a PercentageTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Liver Fat Content Assessed by MRI-PDFFTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Controlled Attenuation Parameter (CAP)Time frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Fasting Blood GlucoseTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in 2-Hour Blood Glucose During an Oral Glucose Tolerance TestTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Glycated Hemoglobin (HbA1c)Time frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in HOMA-betaTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in HOMA-IRTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Total Body Fat Mass Assessed by DXATime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Total Body Tissue Fat Percentage Assessed by DXATime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Total Body Lean Mass Assessed by DXATime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Estimated Visceral Adipose Tissue Mass Assessed by DXATime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Relative Skeletal Muscle Index (RSMI) Assessed by DXATime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Body WeightTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Waist CircumferenceTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Waist-to-Hip RatioTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Waist-to-Height RatioTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Whole-Blood Nicotinamide Mononucleotide (NMN) ConcentrationTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Whole-Blood Nicotinamide Adenine Dinucleotide (NAD+) ConcentrationTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Relative Telomere Length in Peripheral Blood CellsTime frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Peak Oxygen Uptake (Peak VO2)Time frame: Baseline and Week 26
    • AddedChange From Baseline to Week 26 in Oxygen Uptake at the Anaerobic Threshold (VO2-AT)Time frame: Baseline and Week 26
    • RemovedBody composition analysis, expressed in kg, %, and g/cm², evaluated by dual-energy X-ray absorptiometryTime frame: 26 weeks
    • …and 11 more, on the record history on ClinicalTrials.gov ↗
    Title The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and MetablismMetabolism in Middle-aged and Elderly Individuals With Metabolic Disorders.
    + 8 other changes: index terms, verification date, responsible party, description, conditions, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06907329
Lead sponsor
Qing Su
Responsible party
Qing Su (Director, Dept of Endocrinology, Xinhua Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine) — Sponsor-investigator
First posted
Apr 2, 2025
Start date
Jun 5, 2025
Primary completion
Oct 18, 2026
Completion
Oct 18, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotinamide Mononucleotide

Start the discussion